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Abstract: Background: Herpes simplex 1 co-infections in patients with COVID-19 are considered
relatively uncommon; some reports on re-activations in patients in intensive-care units were pub-
lished. The aim of the study was to analyze herpetic re-activations and their clinical manifestations
in hospitalized COVID-19 patients, performing HSV-1 PCR on plasma twice a week. Methods:
we conducted a prospective, observational, single-center study involving 70 consecutive patients
with severe/critical SARS-CoV-2 pneumonia tested for HSV-1 hospitalized at Azienda Ospedaliero-
Universitaria of Modena. Results: of these 70 patients, 21 (30.0%) showed detectable viremia and
13 (62%) had clinically relevant manifestations of HSV-1 infection corresponding to 15 events (4 pneu-
monia, 5 herpes labialis, 3 gingivostomatitis, one encephalitis and two hepatitis). HSV-1 positive
patients were more frequently treated with steroids than HSV-1 negative patients (76.2% vs. 49.0%,
p = 0.036) and more often underwent mechanical ventilation (IMV) (57.1% vs. 22.4%, p = 0.005). In the
unadjusted logistic regression analysis, steroid treatment, IMV, and higher LDH were significantly
associated with an increased risk of HSV1 re-activation (odds ratio 3.33, 4.61, and 16.9, respectively).
The association with the use of steroids was even stronger after controlling for previous use of both
tocilizumab and IMV (OR = 5.13, 95% CI:1.36–19.32, p = 0.016). The effect size was larger when
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restricting to participants who were treated with high doses of steroids while there was no evidence to
support an association with the use of tocilizumab Conclusions: our study shows a high incidence of
HSV-1 re-activation both virologically and clinically in patients with SARS-CoV-2 severe pneumonia,
especially in those treated with steroids.
Keywords: SARS-Cov-2; Herpesviridae; steroids; tocilizumab; re-activation
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia is the
most relevant clinical presentation of COVID-19. SARS-CoV-2 infection may trigger an
uncontrolled systemic inflammatory response (the so-called “cytokine storm”) that is as-
sociated with acute respiratory distress syndrome, lung fibrosis, and long-term adverse
outcomes [1,2]. This inflammatory phase is also characterized by an immunosuppression
state and lymphopenia that is associated with poor outcomes [3,4]. Until now, a few
drugs have been approved to treat patients with SARS-CoV-2 pneumonia. In particular,
despite initial controversy, steroids were proved to reduce mortality in a large randomized
controlled trial [5]. Moreover, other studies suggested a benefit of either antivirals as remde-
sivir and/or immunomodulatory drugs as baricitinib and IL-6 antagonists (tocilizumab
and sarilumab) [6–12]. The efficacy of both antivirals and immunomodulatory drugs de-
pends on the timing of administration. While remdesevir is useful during viral replication,
steroids and immunomodulatory drugs are effective against the cytokine storm and can be
harmful if used in the first days of SARS-CoV-2 infection [5].
The risk of super-infection and viral re-activation is not well known and may be
caused by the interplay between SARS-CoV-2 infection, steroid use, and immunomodula-
tory drugs.
Recent literature suggests that Herpesviridae re-activations are frequent in intensive
care unit (ICU) patients with COVID-19. In particular Herpes simplex virus (HSV) and
cytomegalovirus (CMV) re-activations have been reported at higher rates in these pa-
tients than those described in previous studies in critically ill patients without SARS-
CoV-2 infection [13]. The authors suggested lymphopenia as the probable cause of the
increased incidence of Herpesviridae re-activation, without considering the use of steroids
or tocilizumab [13,14]. Regarding patients in non-ICU wards, only case reports on skin,
oral, and ocular Herpesviridae clinical manifestations in patients with COVID-19 were
published [15–18].
The aim of this analysis was to evaluate HSV-1 re-activation by means of plasma
polymerase chain reaction (PCR) and its clinical presentation in hospitalized patients with
severe/critical SARS-CoV-2 pneumonia.
2. Methods
We conducted a prospective, observational, single-center study analyzing HSV-1 re-
activation in COVID-19 patients admitted to the Azienda Ospedaliero-Universitaria of
Modena, Italy. Between 8 April and 31 May 2020, we performed plasma qualitative PCR
for HSV-1 twice a week in adult COVID-19 patients admitted to hospital. In patients who
tested positive for qualitative HSV-1 PCR, quantitative HSV-1 PCR was performed (see
Supplementary Materials for technical specifications). The date of 8 April was chosen after
2 fatal cases of HSV-1 fulminant hepatitis occurred [19] It was decided to test all admitted
COVID-19 patients in order to quantify the risk of herpetic re-activation. At a later time, in
a subset of the study population, we retrospectively performed HSV-1 PCR on plasma that
was stored at −80 ◦C) from patients at baseline, i.e., before immunosuppressive treatment,
in order to determine if re-activation was already present at hospital admission. Each
patient was followed until discharge or death or up to 15 June 2020.
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In the same period, we also evaluated cytomegalovirus (CMV) re-activations with
blood CMV-DNA; we consider as “high viremia” CMV-DNA > 10,000 UI/mL (see Supple-
mentary Materials for technical specifications).
The Institutional Ethics Committee of Area Vasta Emilia Nord (CE AVEN) approved
the study (approval number 396/2020/OSS/AOUMO—CoV-2 MO-Study) on 5 May 2020.
Due to the observational nature of the study, written informed consent was not required.
All patients presented respiratory symptoms and were diagnosed with SARS-CoV2
by real-time PCR performed on oropharyngeal swab specimens.
Data were collected from electronic medical records, including demographics, biomark-
ers of inflammation and coagulation, immunosuppressive drugs, PCR for HSV-1 on differ-
ent patient specimens (plasma, bronchoalveolar lavage (BAL), cerebrospinal fluid, biopsy),
clinical manifestations compatible with HSV-1 re-activation, antiviral prophylaxis or ther-
apy, and outcomes (use of invasive mechanical ventilation (IMV), and death).
All microbiological samples were analyzed in the local Microbiology and Virology
Laboratory. Technical specifications of HSV-1 PCR and CMV-DNA are described in Supple-
mentary Materials.
2.1. Definitions
Severe COVID-19 infection: individuals who have SpO2 < 94% on room air at sea level, a
ratio of arterial partial pressure of oxygen to fraction of inspired oxygen
(PaO2/FiO2) < 300 mm Hg, respiratory frequency > 30 breaths/min, or lung infiltrates > 50%.
Critical COVID-19 infection: individuals who have respiratory failure, septic shock,
and/or multiple organ dysfunction.
2.2. HSV-1 Re-Activation
HSV-1 re-activation was diagnosed either if target was above the limit of detection
(qualitative result) on plasma or >10,000 copies/mL in BAL quantitative assay [20].
2.3. Standard of Care (SOC)
All patients received SOC treatment at hospital admission according to regional
COVID-19 guidelines of Emilia Romagna [21], and data on treatment of COVID-19 was
updated in April 2020. SOC treatment included oxygen supply to target SaO2 reaching at
least 90%, hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day
on days 2–5, adjusted for estimated creatinine clearance), and low molecular weight heparin
for prophylaxis of deep vein thrombosis according to bodyweight and renal function.
2.4. Tocilizumab Treatment
Patients were considered eligible for tocilizumab treatment if they showed a PaO2/FiO2
ratio < 200 mm Hg or SaO2 < 93% and a PaO2/FiO2 ratio < 300 mm Hg on room air associ-
ated with a >30% decrease in PaO2/FiO2 ratio in the previous 24 h during hospitalization.
Tocilizumab was administered by intravenous or subcutaneous route depending on
the availability of specific formulation. Intravenous tocilizumab was administered at
8 mg/kg bodyweight (up to a maximum of 800 mg) twice, 12 h apart [7,22]. The subcuta-
neous formulation was used when there was a shortage of the intravenous formulation,
at a dose of 162 mg administered in 2 simultaneous doses (i.e., 324 mg in total). In the
analysis, exposure to tocilizumab was fitted as a binary variable (exposed vs. not exposed,
regardless of the formulation).
2.5. Steroid Treatment
Steroids were not routinely administered during the study period (April–May 2020)
outside the ICU; only patients with concomitant COPD received low-dose steroids (methyl-
prednisolone 20 or 40 mg/day). In patients admitted to ICU steroids were administered
for the prevention of pulmonary fibrosis and subsequently defined as ARDS treatment.
Methylprednisolone was administered intravenously with an initial bolus of 0.5 mg/kg
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followed by administration of 0.5 mg/kg 4 times daily for 7 days, 0.5 mg/kg 3 times daily
from day 8 to day 10, 0.5 mg/kg 2 times daily at days 11 and 12 and 0.5 mg/kg once
daily at days 13 and 14. Of note, in case of failed response to tocilizumab, a methylpred-
nisolone bolus at 1 g/d intravenously for 3 consecutive days was administered [23,24]. In
the analysis, exposure to steroids was fitted in 3 separate models as: (i) binary variable
(use vs. no use), (ii) two binary variables comparing low dosage and high dose (bolus or
ARDS) vs. no use, and (iii) per day of any use.
2.6. Statistical Analysis
The main characteristics of the participants at hospital admission, comorbidities, signs
and symptoms, treatment received, and median biomarker levels were compared by HSV-1
status using Chi-square or Mann–Whitney U test, as appropriate.
The analysis focused on the risk of HSV-1 re-activation associated with the use of
tocilizumab and with the use of steroids in separate models.
The association with dose and duration of therapy with steroids was also evaluated
in separate models. Unadjusted and adjusted logistic regression models with HSV-1
re-activation as the binary response variable were fitted.
A different set of potential confounding factors was hypothesized in the 2 models
(Figure S1A,B, Supplementary Materials). For the tocilizumab model, baseline PaO2/FiO2
ratio was the only potential confounder, and steroid use was instead considered a mediator
(Figure S1A, Supplementary Materials). Indeed, during the first wave of the pandemic,
a key trigger for steroid initiation in our clinic was the previous failure of tocilizumab
treatment. In contrast, when use of steroids was chosen as the main exposure of interest,
the directed acyclic graph (DAG) suggested that controlling for both previous tocilizumab
use and of IMV was sufficient to block all the backdoor confounding pathways (Figure S1B,
Supplementary Materials).
We also investigated whether the impact of steroids on the risk of HSV re-activation
might vary in people who were concomitantly treated with tocilizumab or not by formally
testing for the interaction between the two treatments in the model.
3. Results
A total of 70 severe/critical COVID-19 patients were consecutively tested for HSV-1
during their hospital stay between 8 April and 31 May 2020. Of them, a total of 21 (30.0%)
presented detectable HSV-1 viremia. A total of 12 patients out of 21 were also positive on
the quantitative assay, with HSV-1 median viremia of 10,711 copies/mL (IQR 522-110,645).
A total of 13 patients out of 21 (62%) presented HSV-1 clinical manifestations (for a total of
15 events). In particular, 2 patients developed hepatitis (9.5%), 1 of which was fulminant
(4.8%), 4 pneumonia (19%), 5 herpes labialis (23.8%), 3 gingivostomatitis (14.3%), and
1 encephalitis (4.8%). Concerning treatment, 3 patients with herpes labialis (14.3%) received
acyclovir 400 mg two times per day orally, while the other 10 patients (47.6%) with more
severe manifestations received acyclovir 10 mg/kg three times per day intravenously.
At a later time,14 patients (5 in the HSV-1 positive, and 9 in the HSV-1 negative group)
were also tested for the presence of HSV-1 in plasma at hospital admission and all were
negative for HSV-1 replication.
A total of 29 patients out of 70 had a positive CMV-DNA, but only 3 with high viremia
needed treatment.
Concerning SARS-CoV-2 pneumonia severity, median (IQR) PaO2/FiO2 ratio at ad-
mission was 157 mmHg (range 79–296 mmHg) in HSV-negative and 161 mmHg (range
104–187 mmHg) in HSV-positive (p = 0.438). A total of 23/70 (33%) patients underwent IMV,
12 (57.1%) among the HSV-positive and 11 (22.4%) among the HSV-negative (p = 0.005).
In participants who experienced re-activation, the median time from hospital admission
to the event was 19 days (IQR: 8–34). All HSV re-activations in patients who underwent
IMV were diagnosed after a median time of 15 days. Table 1 describes baseline factors and
biomarkers by HSV-1 status.
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Table 1. Baseline characteristics, comorbidities and outcome of COVID-19 patients by HSV-1 status.
HSV-1
Positive Negative p-Value * Total
N = 21 N = 49 N = 70
Patients’ Characteristics
Age, years Median (IQR) 72 (66, 76) 67 (52, 76) 0.185 70 (58, 76)
BMI, Kg/m2 (49) 27.5 (25.6, 32.8) 26.2 (24.2, 29.9) 0.150 26.7 (24.6, 31.1)
Any comorbidity, n (%)
Yes 15 (71.4%) 28 (57.1%) 0.264 43 (61.4%)
Comorbidities, n (%)
Diabetes 6 (28.6%) 8 (16.3%) 0.244 14 (20.0%)
Hypertension 13 (61.9%) 25 (51.0%) 0.406 38 (54.3%)
Cardiovascular Disease 3 (14.3%) 10 (20.4%) 0.549 13 (18.6%)
Chronic Kidney Disease 2 (9.5%) 4 (8.2%) 0.853 6 (8.6%)
Cancer 0 (0.0%) 3 (6.1%) 0.250 3 (4.3%)
Hepatitis B/C 0 (0.0%) 0 (0.0%) 0 (0.0%)
Signs and symptoms, n (%)
Fever, median (IQR) 36 (36, 36) 36 (36, 37) 0.521 36 (36, 36)
Cough 3 (14.3%) 14 (28.6%) 0.205 17 (24.3%)
Myalgia 0 (0.0%) 4 (8.2%) 0.181 4 (5.7%)
Sputum 1 (4.8%) 1 (2.0%) 0.534 2 (2.9%)
Headache 1 (4.8%) 3 (6.1%) 0.823 4 (5.7%)
Haemoptysis 0 (0.0%) 0 (0.0%) 0 (0.0%)
Diarrhea 0 (0.0%) 0 (0.0%) 0 (0.0%)
Systolic pressure, mmHg median (IQR) 129 (120, 140) 110 (101, 130) 0.027 120 (110, 135)
Respiratory rate, % median (IQR) 22 (20, 36) 22 (20, 27) 0.490 22 (20, 30)
BaselinePaO2/FiO2 161 (104, 187) 157 (79, 296) 0.438 159 (80, 285)
SOFA Score 2 (0, 4) 2 (0, 4) 0.730 2 (0, 4)
Markers, Median (IQR)
Haemoglobin, g/L 12.6 (10.3, 13.9) 12.4 (11.4, 13.5) 0.934 12.5 (10.8, 13.8)
White cells, mm3 6510 (5170, 8490) 6180 (5190, 8200) 0.729 6365 (5170, 8490)
Total lymphocytes, N 1791 (570.0, 2519) 1290 (810.0, 2383) 0.984 1358 (700.0, 2519)
Total lymphocytes, % 27.9 (7.8, 30.9) 20.3 (8.8, 36.0) 0.625 22.4 (8.6, 33.9)
Alanine amino-transferase, U/L 39.0 (29.0, 69.0) 48.0 (31.0, 81.0) 0.513 41.5 (29.0, 81.0)
Bilirubin, mg/L 0.6 (0.4, 0.9) 0.5 (0.4, 0.8) 0.366 0.6 (0.4, 0.8)
Calcium, mg/L 8.4 (8.2, 8.7) 8.6 (8.2, 8.9) 0.363 8.5 (8.2, 8.9)
Creatine Kinase, U/L 127.0 (64.0, 305.0) 78.0 (33.0, 180.0) 0.106 97.5 (36.0, 206.0)
Chloride, mmol/L 100.5 (98.0, 104.0) 100.0 (96.0, 103.0) 0.454 100.0 (97.0, 104.0)
Creatinine, mg/L 0.8 (0.7, 1.0) 0.9 (0.7, 1.1) 0.353 0.8 (0.7, 1.1)
D-dimer, mg/L 1200 (810.0, 2650) 900.0 (460.0, 1800) 0.088 1060 (580.0, 2070)
Lactate dehydrogenase, U/L 831.0 (556.0, 998.0) 609.0 (466.0, 745.0) 0.022 652.0 (473.0, 832.0)
C-reactive protein, mg/L 15.5 (5.0, 22.2) 7.5 (4.5, 18.9) 0.405 9.0 (4.5, 19.7)
Platelets, 109/L 182.0 (140.0, 244.0) 180.0 (151.0, 251.0) 0.888 181.0 (149.0, 251.0)
Potassium, mmol/L 3.7 (3.5, 3.9) 3.8 (3.6, 4.0) 0.213 3.7 (3.5, 4.0)
Sodium, mmol/L 137.0 (134.0, 139.0) 136.0 (135.0, 139.0) 0.663 136.0 (135.0, 139.0)
IL−6, mg/L 412.8 (241.1, 1252) 253.4 (78.9, 1418) 0.392 280.5 (92.8, 1349)
Ferritin, mg/L 987.5 (472.5, 1475) 603.5 (416.0, 1562) 0.684 688.0 (423.0, 1518)
Disease Duration
Days from symptoms onset to hospitalisation, median (IQR) 5 (2, 7) 8 (4, 15) 0.572 7 (3, 12)
Days from hospitalisation to intubation, median (IQR) 4 (2, 7) 4 (1, 6) 0.827 4 (2, 6)
Follow-up, days 7 (3, 24) 14 (6, 27) 0.170 13 (6, 25)
Intervention, n (%) 0.027
Tocilizumab subcutaneous 3 (27.3%) 5 (12.5%) 8 (15.7%)
Tocilizumab intravenous 11 (52.4%) 30 (61.2%) 41 (58.6%)
Only SOC 7 (33.3%) 13 (26.5%) 20 (28.6%)
Steroids 16 (76.2%) 24 (49.0%) 0.036 40 (57.1%)
Outcomes
Events, n (%)
Invasive mechanical ventilation 12 (57.1%) 11 (22.4%) 0.005 23 (32.9%)
Death-all 6 (28.6%) 9 (18.4%) 0.344 15 (21.4%)
* Chi-square or Mann–Whitney U or Kruskal–Wallis test as appropriate. HSV: herpes simplex virus; N: number; IQR: interquartile range,
BMI: body mass index; PaO2/FiO2: ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2); SOC: standard
of care.
HSV-positive patients were more frequently treated with steroids than HSV-negative
patients (76.2% vs. 49.0%, p = 0.036) and underwent IMV more frequently (57.1% vs. 22.4%,
p = 0.005). Median systolic blood pressure was higher in HSV-positive patients (129 mmHg
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vs. 110 mmHg, p = 0.027). Regarding baseline biomarkers, only LDH was significantly
higher in HSV-positive patients (831 vs. 609 UI/L, p = 0.022) (see Table 1).
The Kaplan–Meier curve (Figure 1) describes the cumulative incidence of HSV-1
viremia from 8 April 2020, when HSV screening was initiated. By day 10 after that date, the
cumulative probability of experiencing HSV-1 re-activation was 29.1% (95% CI:18.0–40.3%).




Figure 1. Kaplan–Meier estimates of HSV re-activation. 
On the basis of these results, universal HSV prophylaxis was started in all ventilated 
patients from day 19, and only two events (<140 target detected at day 26 and day 40, 
respectively) occurred without clinical manifestations. 
Table 2A,B show the results of the logistic regression analysis investigating the asso-
ciation between the use of specific therapies (e.g., tocilizumab and steroids) on the risk of 
experiencing HSV re-activation. 
Table 2. Logistic regression estimates of the risk of HSV-1 infection. 
(A) 
  Unadjusted Adjusted * 
  Odds Ratio (95% CI) p-Value Odds Ratio (95% CI) p-Value 
Steroids         
Yes (any dose) vs. No 3.33 (1.06, 10.53) 0.040 5.13 (1.36, 19.32) 0.016 
Low dose vs. No 3.06 (0.90, 10.33) 0.072 4.80 (1.20, 19.26) 0.027 
High dose vs. No 4.17 (0.91, 19.18) 0.067 6.16 (1.06, 35.74) 0.043 
per day longer exposure 1.04 (0.89, 1.22) 0.625 1.07 (0.90, 1.26) 0.461 
(B) 
 Unadjusted Adjusted * 
 Odds Ratio (95% CI) p-Value Odds Ratio (95% CI) p-Value 
Use of tocilizumab         
Yes vs. No 1.87 (0.54, 6.53) 0.323 1.91 (0.36, 10.21) 0.452 
(A) * adjusted for previous use of tocilizumab and invasive mechanical ventilation. (B) * adjusted for PaO2/FiO2 ratio. 
HSV: herpes simplex virus; PaO2/FiO2: ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2). 
In the unadjusted logistic regression analysis, use of steroid treatment was associated 
with an increased risk of HSV-1 re-activation (odds ratio [OR] 3.33 95%: 1.06–10.53), p = 
0.04). Use of IMV and higher level of LDH at admission were also associated with a higher 
risk of HSV re-activation [25,26] (OR = 4.61 95% 1.54–13.76, p 0.006, OR 16.90 95% 1.20–
Figure 1. Kaplan–Meier estimates of HSV re-activation.
On the basis of these results, universal HSV prophy axis was started in all ven ilated
patients from day 19, and only two events (<140 target detected at day 26 and 40,
respectively) occurr d without clinical manifestations.
Table 2A,B show the results of the logistic regressi n analysis investigating the associ-
ation between the use of specific therapies (e.g., tocilizumab and steroids) o the risk of
experiencing HSV re-activation.
In the unadjusted logistic regression analysis, use of steroid treatment was associated
with an increased risk of HSV-1 re-activation (odds ratio [OR] 3.33 95%: 1.06–10.53),
p = 0.04). Use of IMV and higher level of LDH at admission were also associated with a
higher risk of HSV re-activation [25,26] (OR = 4.61 95% 1.54–13.76, p = 0.006, OR 16.90 95%
1.20–238.0, p = 0.036, respectively) while there was inconclusive evidence regarding an
association with age and total lymphocyte count (OR 1.40 95% 0.92–2.14, p = 0.114, OR 0.90
95% 0.19–4.17, p = 0.892).
The association with steroid use was even stronger after controlling for previous
use of both tocilizumab and IMV (OR = 5.13, 95% CI:1.36–19.32, p = 0.016). Interestingly,
the effect size was larger when restricting to participants who were treated with a high
dose of steroids, although the statistical power of this analysis was limited. In contrast,
there was no association with steroid therapy duration. Moreover, there was no evidence
to support an association between tocilizumab use and the risk of HSV-1 re-activation.
Nevertheless, there was a signal for an exacerbation of the effect of steroids n the risk of
re-activation in participants who concomitantly used tocilizumab, although the evidence
for such an interaction was weak. In particular, the OR for HSV re-activation was 1.50 (95%
CI 0.16–13.75) in participants who id not use tocilizumab vs. 4.15 (95% CI:1.01–17.1) for
tho e who also used tocilizumab (p = 0.44).
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Table 2. Logistic regression estimates of the risk of HSV-1 infection.
(A)
Unadjusted Adjusted *
Odds Ratio (95% CI) p-Value Odds Ratio (95% CI) p-Value
Steroids
Yes (any dose) vs. No 3.33 (1.06, 10.53) 0.040 5.13 (1.36, 19.32) 0.016
Low dose vs. No 3.06 (0.90, 10.33) 0.072 4.80 (1.20, 19.26) 0.027
High dose vs. No 4.17 (0.91, 19.18) 0.067 6.16 (1.06, 35.74) 0.043
per day longer exposure 1.04 (0.89, 1.22) 0.625 1.07 (0.90, 1.26) 0.461
(B)
Unadjusted Adjusted *
Odds Ratio (95% CI) p-Value Odds Ratio (95% CI) p-Value
Use of tocilizumab
Yes vs. No 1.87 (0.54, 6.53) 0.323 1.91 (0.36, 10.21) 0.452
(A) * adjusted for previous use of tocilizumab and invasive mechanical ventilation. (B) * adjusted for PaO2/FiO2 ratio. HSV: herpes simplex
virus; PaO2/FiO2: ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2).
4. Discussion
Our study shows that almost one-third of patients with severe/critical SARS-CoV-2
pneumonia experienced HSV-1 re-activation, with 62% of them presenting clinical manifes-
tations, including one fulminant hepatitis.
The literature on this topic is scarce. Balc’h et al. showed that 47% (18/38) of SARS-
CoV-2 pneumonia patients undergoing IMV for longer than 7 days had at least one viral
pulmonary re-activation [13]. Herpesviridae re-activation was defined as two consecutive
positive HSV or CMV PCR on tracheal aspirates. Nine patients had HSV re-activation,
2 CMV re-activation, and 7 had both. Patients with Herpesviridae re-activation had
significantly longer duration of IMV compared to patients without. Small case series on
herpetic skin lesions have been published without an evaluation of plasma PCR [27,28].
Furthermore, recently Soffritti et al. showed the presence of oral dysbiosis in COVID-
19 patients compared to matched controls. Notably, oral dysbiosis correlated with symptom
severity (p = 0.006) and increased local inflammation (p < 0.01). In particular, the oral virome
represented 0.07% of the microbial community in controls, compared to 1.12% in COVID-19
patients. HSV-1 and EBV herpesviruses were most present [29].
Actually, in our cohort, patients presented not only plasma re-activation, but also
severe clinical manifestations not previously described. Notably, two patients died of liver
failure due to HSV-1 hepatitis confirmed by liver biopsy, one included in this analysis
and one in a different hospital in our town [19]. Our sample size was sufficiently large
to evaluate the association between type of COVID-19 therapy used and risk of HSV re-
activation, after controlling for a number of identified potential confounders (PaO2/FiO2
ratio, previous use of IMV, and tocilizumab use).
It is reasonable to assume that the immunosuppression caused by SARS-CoV-2 in-
fection, together with steroid treatment and IMV could represent a predisposing factor
for herpes re-activations. In particular, before the present study a number of possible
determinants of HSV-1 re-activation were identified:
1. The role of the virus itself. Indeed, patients with SARS-CoV-2, especially those with
severe pneumonia, have a dysregulated immune response at hospitalization and often
develop immune suppression characterized by lymphopenia, mainly in CD4 and CD8
T cells after the pro-inflammatory phase [30]. This virus-induced immunosuppression,
followed by the administration of immunomodulatory drugs, further blocks the
immune response inhibiting antiviral immunity [31]. In our study, we could test
retrospectively for HSV-1 PCR at hospital admission in only 14 out of 70 patients.
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Despite the low number of tested patients, since they were all negative, this could
suggest that SARS-CoV-2 by itself seems not to play a role in herpes re-activation.
In addition, we could not show any evidence of an association between lymphopenia
and re-activation risk.
2. Tocilizumab. In our cohort, a high percentage of patients received tocilizumab with a
dose higher than that used in rheumatoid arthritis [32]. In that setting, no clinically
relevant manifestations of HSV-1 were described [33] and Gron et al. reported antiviral
prescription in 5% of patients treated with tocilizumab without specifying the clinical
reason [34]. Only one case of Herpes zoster meningitis was reported [35]. In the
setting of hematological patients after CAR-T-cell infusion no statistically significant
differences in risk of HSV-1 infection due to tocilizumab were reported but patients
underwent herpes prophylaxis [22].
Our data do not support a role of tocilizumab on HSV re-activation in COVID-19
patients, although we hypothesized this at the time of the two fulminant hepatitis cases [19].
Actually, we found little difference in the prevalence of use of tocilizumab between HSV-
positive and HSV-negative participants and after controlling for confounders, the data were
highly compatible with the null hypothesis of no association. In addition, we found some
evidence that the risk associated with use of steroids could be exacerbated by concomitant
use of tocilizumab (>2-fold risk difference in the additive scale) but larger studies are
needed to confirm this observation. In fact, even if the p-value is 0.44, it is possible that
tocilizumab is an effect measure modifier.
3. IMV. It is well known that herpes re-activation is a common finding in patients admit-
ted to ICU. In a pre-COVID study evaluating 201 patients with prolonged (>4 days)
IMV, Luyt et al. found that 20% had HSV bronchopneumonitis with cytological
and/or histological signs of deep lung infection [36]. In our analysis 57.1% of patients
with HSV re-activation underwent IMV, that in the unadjusted analysis was associated
with HSV-1 re-activation.
4. Steroid treatment. Steroids may exacerbate herpetic re-activation of latent virus, es-
pecially among patients undergoing other stress-inducing or immunosuppressive
therapies such as irradiation or chemotherapy [37]. Case reports have been described
in patients with inflammatory bowel disease [38]. Our analysis shows convincing evi-
dence for an association between use of steroids and risk of HSV-1 re-activation. The
association was even stronger after controlling for previous use of both tocilizumab
and IMV (OR = 5.13, p = 0.016). Interestingly, the effect size was larger when restrict-
ing to participants who were treated with high-dose steroids, while there was no
association with duration of steroid treatment.
This evidence is even more relevant since after the period described in the study, the
RECOVERY trial showed that dexamethasone decreases mortality in patients with oxygen
need and it is now considered the SOC in patients hospitalized for SARS-CoV-2 pneumonia.
Our observations had an important clinical impact in response to the first wave of
COVID-19 pandemic as they prompted around the end of April 2020 the initiation of
acyclovir prophylaxis in all patients with SARS-CoV-2 pneumonia either admitted to ICU
or in non-invasive ventilation. In all the other patients, we continued to perform HSV-
1 plasma PCR twice a week and we started prophylaxis or treatment according to test
results. After the implementation of acyclovir prophylaxis, we observed no new clinical
manifestations due to HSV-1 re-activation.
Luyt et al. recently published a randomized clinical trial in 238 adults demonstrating
that, in patients receiving mechanical ventilation for 96 h or more with HSV re-activation in
the throat, use of acyclovir, 5 mg/kg, 3 times daily for 14 days, did not increase the number
of ventilator-free days at day 60, compared with placebo [39]. The observed difference for
mortality was nonsignificant but may be worthy of further investigation in subsequent
more highly powered studies.
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Our study has some limitations: first of all, it is a single-center study enrolling severely
to critically ill patients, thus, results cannot be generalized to all COVID-19 patients;
second, screening for HSV-1 was not performed routinely in all admitted patients as it was
prompted by a serious adverse event. However, since participant inclusion was systematic
on the basis of calendar date, this is unlikely to have introduced important selection bias.
Due to this limitation, we have HSV-PCR at admission only in 14 patients out of 70. Finally,
because of the observational nature of the study, we cannot prove that steroid use was a
cause of the episodes of HSV-1 re-activations observed.
Our study has some strengths: it is the first study that analyzed the incidence and
clinical implications of HSV-1 re-activation in patients with SARS-CoV-2 pneumonia;
second it has strong clinical and therapeutic implications for COVID-19 patients, especially
in the present and future waves of hospitalized patients most of whom are treated with
steroids, which is now considered the SOC.
In conclusion, our study shows a high incidence of both virological and clinical HSV-
1 re-activation in patients with SARS-CoV-2 severe/critical pneumonia. Data show an
association between this risk and treatment with steroids, which could not be explained
by age, previous IMV, and level of inflammation at hospital admission. Further studies
are needed, especially a randomized controlled trial, to confirm the utility of acyclovir
prophylaxis in COVID-19 patients with severe pneumonia admitted to the hospital.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.339
0/microorganisms9091896/s1. Technical specifications: HSV-1 PCR; CMV PCR. Figure S1 (A) assumption
for the underlying structure of the data for the model with use of tocilizumab as the key exposure,
(B) assumption for the underlying structure of the data for the model with use of steroids as the key exposure.
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